Evidence map›Paper›PMID 32365141›Full record

ArticlePLoS pathogens2020

Revisiting promyelocytic leukemia protein targeting by human cytomegalovirus immediate-early protein 1.

Christina Paulus, Thomas Harwardt, Bernadette Walter, Andrea Marxreiter, Marion Zenger, Edith Reuschel, Michael M Nevels

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Evidence for Tethering of Human Cytomegalovirus Genomes to Host Chromosomes.Frontiers in cellular and infection microbiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Christina PaulusBiomedical Sciences Research Complex, University of St Andrews, St Andrews, United Kingdom.ORCID 0000-0002-4123-5629
Thomas HarwardtInstitute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Bernadette WalterBiomedical Sciences Research Complex, University of St Andrews, St Andrews, United Kingdom.ORCID 0000-0003-2548-4577
Andrea MarxreiterInstitute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Marion ZengerInstitute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
Edith ReuschelDepartment of Obstetrics and Gynecology, Clinic St. Hedwig at Hospital Barmherzige Brüder Regensburg, Regensburg, Germany.ORCID 0000-0001-5841-1812
Michael M NevelsBiomedical Sciences Research Complex, University of St Andrews, St Andrews, United Kingdom.ORCID 0000-0002-7115-407X
Institute of Medical Microbiology and Hygiene · DEUniversity of St Andrews · GBKrankenhaus Barmherzige Brüder · DE

Funding

Medical Research Council MR/P022146/1Wellcome Trust
6 · The paper itself

Abstract

Promyelocytic leukemia (PML) bodies are nuclear organelles implicated in intrinsic and innate antiviral defense. The eponymous PML proteins, central to the self-organization of PML bodies, and other restriction factors found in these organelles are common targets of viral antagonism. The 72-kDa immediate-early protein 1 (IE1) is the principal antagonist of PML bodies encoded by the human cytomegalovirus (hCMV). IE1 is believed to disrupt PML bodies by inhibiting PML SUMOylation, while PML was proposed to act as an E3 ligase for IE1 SUMOylation. PML targeting by IE1 is considered to be crucial for hCMV replication at low multiplicities of infection, in part via counteracting antiviral gene induction linked to the cellular interferon (IFN) response. However, current concepts of IE1-PML interaction are largely derived from mutant IE1 proteins known or predicted to be metabolically unstable and globally misfolded. We performed systematic clustered charge-to-alanine scanning mutagenesis and identified a stable IE1 mutant protein (IE1cc172-176) with wild-type characteristics except for neither interacting with PML proteins nor inhibiting PML SUMOylation. Consequently, IE1cc172-176 does not associate with PML bodies and is selectively impaired for disrupting these organelles. Surprisingly, functional analysis of IE1cc172-176 revealed that the protein is hypermodified by mixed SUMO chains and that IE1 SUMOylation depends on nucleosome rather than PML binding. Furthermore, a mutant hCMV expressing IE1cc172-176 was only slightly attenuated compared to an IE1-null virus even at low multiplicities of infection. Finally, hCMV-induced expression of cytokine and IFN-stimulated genes turned out to be reduced rather than increased in the presence of IE1cc172-176 relative to wild-type IE1. Our findings challenge present views on the relationship of IE1 with PML and the role of PML in hCMV replication. This study also provides initial evidence for the idea that disruption of PML bodies upon viral infection is linked to activation rather than inhibition of innate immunity.

Indexed as

Cytomegalovirus InfectionsImmediate-Early ProteinsImmunity, InnatePromyelocytic Leukemia ProteinVirus ReplicationCell LineCytomegalovirusGene Expression Regulation, ViralHumansMutationSumoylationIE1 protein, cytomegalovirusImmediate-Early ProteinsPML protein, humanPromyelocytic Leukemia Protein

Identifiers

PMID32365141
PMCPMC7224577
OpenAlexW3021444848

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.